Acetaminophen and atherosclerosis
This article was originally published in The Tan Sheet
OTC analgesic inhibits an enzyme that can increase the unhealthy properties of low-density lipoproteins, Philip Greenspan, PhD, University of Georgia College of Pharmacy, reports at a conference co-sponsored by the American Heart Association and the North American Vascular Biology Organization in Denver May 21. The in vitro study - funded in part by Tylenol marketer McNeil Consumer Healthcare - aimed to examine the mechanism of effect acetaminophen has been shown to have on LDL and atherosclerosis (1"The Tan Sheet" Nov. 29, 1999, p. 24). The results suggest acetaminophen acts to inhibit myeloperoxidase, an enzyme associated with the disease-causing potential of LDL cholesterol. The study is being prepared for publication
You may also be interested in...
Clinically relevant doses of acetaminophen significantly decrease aortic fatty streak and total aortic area in hypercholesterolemic rabbits compared to placebo, Addison Taylor, MD/PhD, et al., Baylor College of Medicine, report in a study abstract presented at the American Heart Association annual meeting in Atlanta Nov. 10. The 12 rabbits, which received 100 mg/day acetaminophen through drinking water, also demonstrated significantly lower concentrations of five oxysterols in nmol/mg low density lipoprotein compared to 11 control rabbits. The rabbits all were fed a diet containing 1% cholesterol, with blood being collected
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Perrigo promotes in pricing, planning